Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05033028 · ClinicalTrials.gov registry record · Phase 3
Smartphones for Opiate Addiction Recovery
A Phase 3 study of Opioid Use Disorder, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 2
- Study locations
NCT05033028 is a Phase 3 study of Opioid Use Disorder that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 225 participants, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05033028, a Phase 3 study of Opioid Use Disorder, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 2
- Study locations
Study Summary
Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates the numerical probability that a patient will reuse illicit opiates within the next 7-10 days.
Conditions Studied
Interventions
- OTHER Smartphone app
Study Locations (2)
New Jersey
- Rutgers University - Piscataway
New York
- NYU Langone - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2021-11-01 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05033028
The ClinicalTrials.gov registry entry for NCT05033028 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,655-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (95% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 1 intervention - of which Smartphone app is the first listed.
NCT05033028 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT05033028 about?
NCT05033028 is a clinical study titled "Smartphones for Opiate Addiction Recovery". Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates the...
What is the current status of trial NCT05033028?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2021-11-01. Estimated completion is 2027-05-31.
What conditions does trial NCT05033028 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT05033028?
The interventions under investigation include: Smartphone app (OTHER).
Who is sponsoring clinical trial NCT05033028?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05033028 being conducted?
This trial has 2 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Buprenorphine for Individuals in Jail
RECRUITING · Phase 3
-
Standard Versus High Dose ED-Initiated Buprenorphine Induction
RECRUITING · Phase 3
-
Treating Polysubstance Use Using a Novel Digital Technology
RECRUITING · Phase 3
-
High Dose Buprenorphine (BUP) Induction in the Emergency Department (ED)
RECRUITING · Phase 3
-
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
RECRUITING · Phase 3
-
Transdermal Patch for BupRenorphine Induction DurinG PrEgnancy (Patch BRIDGE)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.